Abstract |
Pulmonary arterial hypertension (PAH) is an infrequent but nevertheless serious life threatening severe complication of human immunodeficiency virus ( HIV) infection. In today's era of antiretroviral therapy (ART), the mortality of HIV patients has greatly reduced due to improved immune function and fewer opportunistic infections. However, these patients have an increased incidence of PAH. In this review, we will mainly discuss HIV-related pulmonary arterial hypertension (HRPH) in terms of the epidemiology, pathogenesis, clinical characteristics and treatment.
|
Authors | Hai-Long Dai, Ming Zhang, Zhi-Cheng Xiao, Xue-Feng Guang, Xiao-Long Yin |
Journal | Heart, lung & circulation
(Heart Lung Circ)
Vol. 23
Issue 4
Pg. 299-302
(Apr 2014)
ISSN: 1444-2892 [Electronic] Australia |
PMID | 24345377
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Copyright | Copyright © 2013 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved. |
Topics |
- HIV Infections
(complications, epidemiology, pathology, physiopathology, therapy)
- HIV-1
- Humans
- Hypertension, Pulmonary
(epidemiology, etiology, pathology, therapy)
|